Immunorevive Therapeutics

Immunorevive Therapeutics specializes in developing novel immunotherapies for treating late-stage cancers, particularly those that have failed standard treatments.

Co-founder and biologist Jane Thompson dropped out of a prestigious university to pivot her research from basic science to applying engineered antibodies that re-sensitize immune systems to previously ineffective drugs. A pivotal contract with a space agency in 3021 validated her approach, launching her company into the medical research spotlight.